Slide 1: The Future of Cardiac Care
The Future of Cardiac Care Fourth Quarter and Full Year 2024 Financial Results Conference Call NASDAQ: BEAT MARCH 13, 2025
Slide 2: Disclaimers
Fourth Quarter Full Year 2024 Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial positio
Slide 3: Agenda: On the Call Today
Fourth Quarter Full Year 2024 Results Conference Call Agenda: On the Call Today: COMPANY OVERVIEW OPERATIONAL UPDATES COMPANY MILESTONES GO TO MARKET STRATEGY Rob Eno Tim Cruickshank FINANCIAL RESULTS CEO CFO CLOSING SUMMARY 3
Slide 4: HeartBeam: Total Heart Intelligence…Wherever You Are
Fourth Quarter Full Year 2024 Results Conference Call COMPANY OVERVIEW HeartBeam: Total Heart Intelligence…Wherever You Are Unique IP-Enabled Highest Resolution Massive Market Roadmap with Clear Go To Market Disruptive Technology Cardiac Data Opportunity Clear Focus Areas Strategy First ever cable-f
Slide 5: Key Developments Since Last Update
Fourth Quarter Full Year 2024 Results Conference Call OPERATIONAL UPDATES Key Developments Since Last Update REGULATORY • Received foundational FDA Clearance for the HeartBeam System PATHWAY • Submitted the FDA 510(k) application for 12-lead (“12L”) Synthesis software • Pivotal study results on 12L
Slide 6: Continued Recognition for HeartBeam's Innovative Technology
Fourth Quarter Full Year 2024 Results Conference Call OPERATIONAL UPDATES Continued Recognition for HeartBeam’s Innovative Technology • Awarded 𝗗𝗶𝗮𝗺𝗼𝗻𝗱 𝗣𝗶𝗻𝗻𝗮𝗰𝗹𝗲 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗔𝘄𝗮𝗿𝗱 in Medical Device Innovation. • Recognizes companies making significant contributions to…
Slide 7: Near-term Milestones: Presented on November 2024 Call
Fourth Quarter Full Year 2024 Results Conference Call COMPANY MILESTONES Near-term Milestones: Presented on November 2024 Call 2024 2025 Regulatory Clinical Commercial HeartBeam System FDA Clearance Foundational Clearance VALID-ECG FDA Clearance 12L Synthesis Software Enrollment FDA 510(k) Submissio
Slide 8: Executing on Cadence of Near-term Milestones
Fourth Quarter Full Year 2024 Results Conference Call COMPANY MILESTONES Executing on Cadence of Near-term Milestones 2024 2025 Regulatory Clinical Commercial HeartBeam System FDA Clearance Foundational Clearance VALID-ECG FDA Clearance 12L Synthesis Software Enrollment FDA 510(k) Submission Complet
Slide 9: Early Access Program Providing Key Insights
Fourth Quarter Full Year 2024 Results Conference Call GO TO MARKET STRATEGY Early Access Program Providing Key Insights • Early Access Program commenced in Q1’25 • Attain key learnings between now and 510(k) Clearance for 12L synthesis software in preparation for pilot commercialization • Goals of E
Slide 10: GTM Phases: Expanding Use Cases as Clinical Evidence Grows
Fourth Quarter Full Year 2024 Results Conference Call GO TO MARKET STRATEGY GTM Phases: Expanding Use Cases as Clinical Evidence Grows SEGMENT FOCUS AREAS Phase 1 Direct Patient Pay • Concierge and preventive cardiology practices • Supplement with direct patient outreach in target geographies • Indi
Slide 11: Focus of Initial Commercial Launch: Direct Patient Pay
Fourth Quarter Full Year 2024 Results Conference Call GO TO MARKET STRATEGY Focus of Initial Commercial Launch: Direct Patient Pay TARGET PATIENT • Known cardiac issue/higher risk/family history OVERALL STRATEGY PROFILE • Proactive/concerned with cardiac health • Willingness and ability to pay witho
Slide 12: Financial Discipline Aligned to Achieving Milestones
Fourth Quarter Full Year 2024 Results Conference Call FINANCIAL RESULTS Financial Discipline Aligned to Achieving Milestones • Net cash used in operating activities of $ in Thousands Year Ended December 31, $14.5M for FY’24, a 20% increase year-over- 2024ii 2023 year (“YoY”). Operating Expenses:
Slide 13: Closing Summary
Fourth Quarter Full Year 2024 Results Conference Call Closing Summary • Foundational FDA clearance achieved EXECUTING ON • FDA 510(k) application for 12L synthesis software submitted NEAR-TERM • Pivotal study results on 12L synthesis software accepted for presentation at HRS MILESTONES • Completed $
Slide 14: Q&A
Q&A Company Investor Relations Tim Cruickshank Chris Tyson CFO Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050